XPC 418
Alternative Names: XPC-418Latest Information Update: 09 Jan 2025
Price :
$50 *
At a glance
- Originator Xenon Pharmaceuticals
- Class Antiepileptic drugs; Small molecules
- Mechanism of Action NAV1.1 voltage-gated sodium channel stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dravet syndrome
Most Recent Events
- 06 Dec 2024 Preclinical trials in Dravet syndrome in Canada (unspecified route)
- 06 Dec 2024 Pharmacodynamics data from a preclinical study in Dravet syndrome released by Xenon Pharmaceuticals
- 30 Nov 2024 Xenon Pharmaceuticals announces intention to submit IND applications to for Dravet syndrome in 2025